Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)
Open Access
- 14 September 2017
- journal article
- Published by American Society of Hematology in Blood
- Vol. 130 (11) , 1377-1380
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Histiocytoses: emerging neoplasia behind inflammationThe Lancet Oncology, 2017
- Efficacy of the MEK inhibitor cobimetinib for wild‐type BRAF Erdheim‐Chester diseaseBritish Journal of Haematology, 2016
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsNew England Journal of Medicine, 2015
- Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester DiseaseJournal of Clinical Oncology, 2015
- Recurrent RAS and PIK3CA mutations in Erdheim-Chester diseaseBlood, 2014
- Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseBlood, 2014
- Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutationBlood, 2013
- High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosesBlood, 2012
- CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patientsBlood, 2011
- Cardiovascular Involvement, an Overlooked Feature of Erdheim-Chester DiseaseMedicine, 2004